Skip to main content
TAKARA BIO INC. logo

TAKARA BIO INC. — Investor Relations & Filings

Ticker · 4974 ISIN · JP3460200003 LEI · 529900OUPLSGTCWC5447 T Manufacturing
Open in API
Filings indexed 72 across all filing types
Latest filing 2024-06-28 AGM Information
Country JP Japan
Listing T 4974

About TAKARA BIO INC.

https://www.takarabio.com/?srsltid=AfmB…

Takara Bio Inc. is a biotechnology company that develops and supplies a wide range of high-quality, innovative tools for life science research. Its portfolio includes kits, reagents, and instruments that support investigations into gene discovery, regulation, and function. In addition to research products, the company provides comprehensive services, including single-cell analysis, stem cell services, and contract development and manufacturing (CDMO) services, particularly for the regenerative medicine sector. Takara Bio is also actively engaged in the development of gene-based therapies, conducting clinical trials for diseases such as cancer. The company's mission is to accelerate scientific discovery and contribute to human health through its advanced biotechnologies.

Recent filings

Filing Released Lang Actions
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being filed because resolutions were passed at the Annual General Meeting (AGM) held on June 21, 2024, pursuant to financial regulations. Section 2 details the resolutions, which include the approval of the dividend distribution (剰余金処分の件) and the election of directors and auditors. The core content is the official results of the shareholder vote (賛成, 反対, 棄権) from the AGM. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at any general meeting.
2024-06-28 Japanese
内部統制報告書－第22期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the legal basis "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1), which mandates the filing of an Internal Control Report by listed companies in Japan. The content discusses the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of the fiscal year-end (March 31, 2024). This directly corresponds to the requirements for an Internal Control Report, which is a specific type of regulatory disclosure in Japan, often filed alongside the 10-K equivalent (which is the Annual Securities Report in Japan, but the specific document type here is the control report itself). Given the provided classification codes, this document is a specific regulatory report focusing on internal controls. It is not a general Annual Report (10-K), an Audit Report (AR), or an Earnings Release (ER). Since there is no specific code for 'Internal Control Report', I must select the closest fit or the fallback. In many contexts, the Internal Control Report is a mandatory component of the annual filing package. However, based on the provided definitions, 'Audit Report / Information (AR)' is the closest category that deals with assurance/control testing results, although 'AR' is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests'. Since this is a formal report on internal controls, and not a general regulatory filing (RNS) or a management discussion (MDA), and it is a comprehensive report (not a short announcement), I will evaluate the options. None of the codes perfectly match 'Internal Control Report'. Given the nature of mandatory financial reporting assurance, 'AR' (Audit Report / Information) is the most plausible category among the specific options, as internal control reports are closely related to the audit process. If 'AR' is strictly limited to external audit reports, then 'RNS' (Regulatory Filings) would be the fallback. Given the high specificity of the document content (Internal Control Report), I will lean towards the most relevant functional category, which is often grouped with audit/assurance documents, which is 'AR'. However, since the document is a formal, comprehensive report and not a short announcement, I will classify it as 'AR' as it pertains to internal control assurance, which is a key component of financial reporting integrity. Revisiting the definitions: 'AR' is for 'Standalone audit reports... and results of internal or regulatory stress tests'. This document is the *management's* report on internal controls, not the external auditor's opinion. Therefore, it is a specific regulatory disclosure that doesn't fit the defined categories well. I will use the fallback 'RNS' (Regulatory Filings) as it is a mandatory, specific regulatory document that doesn't match the other detailed categories (like 10-K, ER, IR, etc.). The document length (2112 chars) is substantial enough to be the report itself, not just an announcement (RPA).
2024-06-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2024
2024-06-27 Japanese
有価証券報告書－第22期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers the fiscal year from April 1, 2023, to March 31, 2024, and includes detailed financial statements, management indicators, and corporate history. This is the Japanese equivalent of a 10-K filing. FY 2024
2024-06-27 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies the period covered: "第22期第３四半期（自2023年10月１日 至2023年12月31日）". It also includes confirmation statements regarding the appropriateness of the report's contents, which is characteristic of a formal quarterly filing. This directly corresponds to the definition of an Interim / Quarterly Report (IR). The document length is very short (571 chars), but the content is the substance of the report confirmation itself, not just an announcement of publication, making IR the most appropriate classification over RPA or RNS.
2024-02-14 Japanese
四半期報告書－第22期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report
2024-02-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.